Microdosing Ozempic is catching on, but doctors quoted by The Print warn that unsupervised dose changes may bring weight regain and poorer blood sugar control.
Recap by typeshit. Full story at The Print on MSN.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
The review says incretin drugs can reduce sleep apnea severity in adults with obesity, alongside weight loss and some heart and metabolic gains.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Loading…